Sta-5326 mesylate    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease4

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-002857-29-HU
(EUCTR)
04/01/200618/08/2005A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s DiseaseA Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease Moderate to severe, active Crohn’s disease
MedDRA version: 3.2;Level: LLT;Classification code 10011401
Product Name: STA-5326 mesylate
Product Code: S38
Other descriptive name: STA-6838, STA-5326 m, S38
Synta Pharmaceutical CorporationNULLNot RecruitingFemale: yes
Male: yes
282Hungary
2NCT00250198
(ClinicalTrials.gov)
November 3, 20055/11/2005The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's DiseaseA Randomized, Double-blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's DiseaseCrohn's DiseaseDrug: STA-5326National Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 Years75 YearsAll12Phase 2United States
3NCT00234741
(ClinicalTrials.gov)
November 20055/10/2005Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's DiseaseA Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's DiseaseCrohn's DiseaseDrug: STA-5326 mesylateSynta Pharmaceuticals Corp.National Institute of Allergy and Infectious Diseases (NIAID);National Institutes of Health (NIH)Completed18 Years75 YearsBoth12Phase 2United States
4NCT00138840
(ClinicalTrials.gov)
August 200526/8/2005Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's DiseaseA Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for the Induction of Clinical Response in Patients With Crohn's DiseaseCrohn's DiseaseDrug: STA-5326 mesylateSynta Pharmaceuticals Corp.NULLCompleted18 Years75 YearsBoth282Phase 2United States;Canada